Lichen planus
Drug research and approvals for lichen planus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 24 studies of lichen planus are recruiting on ClinicalTrials.gov, and Health Canada has authorized 2 drug trials for it since 2013.
- Recruiting worldwide: 24
- Trials authorized in Canada: 2
- FDA orphan approvals: 0
- EU medicines: 0
- Study of Modzatinib (ATI-2138) in Adult Participants With Biopsy-proven Forms of Lichen Planus Not Adequately…NCT07935590 · Phase 2 · Aclaris Therapeutics, Inc. · starts Nov 1, 2026
- Salivary IL-8 and Serum IL-6 as Biomarkers for Oral Potentially Malignant Disorders in Smokers and Never-SmokersNCT07915570 · Not reported · British University In Egypt · starts Oct 1, 2026
- A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe…NCT07775924 · Phase 2 · Novartis Pharmaceuticals · starts Sep 29, 2026
- Observational Study of OROSEDAL in Sore Throat and Minor Oral LesionsNCT07620353 · Not reported · Laboratoires Elerte · starts Mar 5, 2026
- A Phase 2/3 Study of Brepocitinib in Adults With Lichen PlanopilarisNCT07532603 · Phase 2 / Phase 3 · Priovant Therapeutics, Inc. · starts Mar 19, 2026
- Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter…NCT07492251 · Phase 2 · Centre Hospitalier Universitaire de Nice · starts Oct 1, 2026
- Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia…NCT07487948 · Phase 2 · Icahn School of Medicine at Mount Sinai · starts May 19, 2026
- Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.NCT07396168 · Phase 4 · The Skin Center Dermatology Group · starts Feb 1, 2026
- Photobiomodulation, Photodynamic Therapy, and Clobetasol in the Treatment of Oral Lichen Planus.NCT07278999 · Not applicable · Medical University of Silesia · starts Dec 1, 2025
Phase 3 1
- PimecrolimusFK506-binding protein 1A inhibitor
Phase 2 12 of 15
- EtanerceptTNF-alpha inhibitor
- RuxolitinibTyrosine-protein kinase JAK1 inhibitor
- Lycopene
- BaricitinibTyrosine-protein kinase JAK1 inhibitor
- Clobetasol propionateGlucocorticoid receptor agonist
- MechlorethamineDNA inhibitor
- Triamcinolone acetonideGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- AlefaceptT-cell surface antigen CD2 inhibitor
- HydroxychloroquineFerriprotoporphyrin IX inhibitor
- AlitretinoinRetinoid receptor agonist
- ApremilastPhosphodiesterase 4 inhibitor
Phase 1 or earlier 1
- IxekizumabInterleukin 17A inhibitor
How its trials ended
177 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 33 whose ending is known, 58% met their primary endpoint, 3% missed it and 39% stopped early.
- Completed, result not reported7542%
- Ongoing3721%
- Status unknown3218%
- Met its primary endpoint1911%
- Stopped: other or unclear63%
- Stopped: enrollment or feasibility53%
- Missed its primary endpoint11%
- Stopped: sponsor or business decision11%
- Stopped: funding11%
| Jul 18, 2018 | The apolp trial: a single-center, randomized, 16 weeks, explanatory, parallel group, superiority, blinded, placebo-controlled, clinical trial of apremilast use…Apremilast | Sunnybrook Research Institute | Ongoing |
| Jul 10, 2018 | A randomized, double-blind, placebo-controlled, parallel group clinical study to assess the safety and efficacy of three doses of clobetasol propionate when…Clobetasol | Afyx Therapeutics A/S | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA